ABSTRACT
RESUMEN INTRODUCCIÓN: Los pacientes con compromiso del sistema inmune pueden desarrollar una enfermedad neurológica incapacitante e incluso mortal, como lo es la leucoencefalopatía multifocal progresiva (LMP) producida por el virus de John Cunningham (JC). PRESENTACIÓN DEL CASO: Se presenta el caso de un hombre de 26 años con diagnóstico reciente de infección por virus de la inmunodeficiencia humana (VIH) que presentó síntomas constitucionales, déficit neurológico progresivo por hemiparesia espástica izquierda, disminución de la agudeza visual y cambios comportamentales. En las imágenes de resonancia magnética (IRM) cerebral contrastada se encontró afectación subcortical difusa de la sustancia blanca con compromiso de las fibras en U que, correlacionado con una prueba de reacción en cadena de la polimerasa (PCR) para virus JC en LCR, confirmó el diagnóstico de LMP. DISCUSIÓN: La LMP puede manifestarse por medio de síntomas cognitivos usualmente imperceptibles para el clínico, pero también como déficit sensorio-motor y visual que se puede corroborar en las IRM al identificar las lesiones típicas en la sustancia blanca, o bien por medio de detección del virus por PCR en líquido cefalorraquídeo. El manejo específico de la causa que desencadenó la inmunosupresión sigue siendo el pilar de tratamiento. CONCLUSIÓN: La mínima sospecha diagnóstica en aquellos pacientes con factores de riesgo y manifestaciones clínicas concordantes con la enfermedad debe llevar a que se confirme el diagnóstico y que se inicie prontamente el manejo terapéutico en búsqueda de restablecer la respuesta inmune.
ABSTRACT INTRODUCTION: Patients with immunocompromised or weakened immune system can develop a disabling and even life-threatening neurological disorder such as progressive multifocal leukoencephalopathy (PML) caused by John Cunningham (JC) virus. CASE PRESENTATION: We present the case of a 26-year-old man with a recent diagnosis of human immunodeficiency virus (HIV) infection who presented constitutional symptoms, progressive neurological deficit due to left spastic hemiparesis with decreased visual acuity and behavioral changes. The brain Magnetic Resonance Imaging (MRI) showed diffuse subcortical involvement of the white matter including the U-fibers, which, correlated with a detection of JC virus DNA by polymerase chain reaction (PCR) cerebrospinal fluid, confirmed the diagnosis of PML. DISCUSSION: PML can range from subtle cognitive impairment imperceptible to the clinician to sensory-motor deficits and visual disturbances that can be corroborated in MRI by identifying the typical lesions in the white matter or by detecting the virus by PCR in cerebrospinal fluid. The specific management of the cause that triggered the immunosuppression continues to be the mainstay of treatment. CONCLUSION: At the minimum diagnostic suspicion in patients with risk factors and clinical manifestations consistent with the disease should proceed to confirm the diagnosis and promptly immune reconstitution.
Subject(s)
Leukoencephalopathy, Progressive Multifocal , Immunocompromised Host , HIV , JC VirusABSTRACT
Abstract INTRODUCTION: Progressive multifocal leukoencephalopathy (PML) is a demyelinating disease of the central nervous system caused by reactivation of JC virus (JCV). METHODS: We described the profile of laboratory-confirmed PML cases among AIDS patients. RESULTS: A total of 43 HIV patients with clinical conditions compatible with PML were obtained; 5 cases were confirmed by JCV testing. The main clinical finding was mental confusion. Median CD4 count was 54 cells/mm³. CONCLUSIONS: Three of the five confirmed PML cases died; the time between diagnosis and death was 2, 5, and 6 months. It is important to consider JCV infection as a differential diagnosis.
Subject(s)
Humans , HIV Infections , Acquired Immunodeficiency Syndrome , Leukoencephalopathy, Progressive Multifocal/diagnosis , JC Virus/genetics , DNA, Viral , CD4 Lymphocyte CountABSTRACT
Progressive multifocal leukoencephalopathy (PML) is a feared entity that occurs most frequently in conditions of extreme immunodeficiency. The diagnosis is often made long after the onset of symptoms due to the physicians' unfamiliarity, and the unavailability of diagnostic tests in some medical centers. Although the incidence of PML is decreasing among HIV patients with the advent of highly active antiretroviral therapy (HAART), in Brazil this entity is the fourth highest neurological complication among these patients. The authors present the case of a middle-aged man who tested positive for HIV concomitantly with the presentation of hyposensitivity in the face and the right side of the body, accompanied by mild weakness in the left upper limb. The clinical features worsened rapidly within a couple of weeks. The diagnostic work-up pointed to the working diagnosis of PML after brain magnetic resonance imaging; however, the detection of the John Cunningham virus (JCV) in the cerebral spinal fluid was negative. HAART was started but the patient died after 7 weeks of hospitalization. The autopsy revealed extensive multifocal patchy areas of demyelination in the white matter where the microscopy depicted demyelination, oligodendrocytes alterations, bizarre atypical astrocytes, and perivascular lymphocytic infiltration. The immunohistochemistry was positive for anti-SV40, and the polymerase chain reaction of the brain paraffin-embedded tissue was positive for JCV. The authors highlight the challenges for diagnosing PML, as well as the devastating outcome of PML among HIV patients.
Subject(s)
Humans , Male , Adult , Acquired Immunodeficiency Syndrome/complications , Leukoencephalopathy, Progressive Multifocal/diagnosis , Autopsy , Leukoencephalopathy, Progressive Multifocal/pathology , Fatal Outcome , JC VirusABSTRACT
ABSTRACT Objectives: To investigate the prevalence of human polyomavirus (BK and JC viruses) infection in peripheral blood mononuclear cells of healthy blood donors. Methods: The study included 250 healthy blood donors. Five-milliliter blood was drawn into sterile EDTA tubes and PBMCs were isolated from whole blood. The isolated PBMCs were counted and stored at −70 °C for future investigation. DNA was extracted and subjected to simple, sensitive and specific semi-nested PCR as well as QPCR using both general and specific primers for different assays. Results: Of 250 blood samples, 66 (26.4%) were positive for BKV DNA (146-34,514 copies/106 cells). JC DNA was found in 45 (18%) blood samples (65-21,250 copies/106 cells). Co-infection with these viruses were found in 11 (4.4%) out of 250 blood samples. Discussion: Our study provides important data on polyomavirus infection in peripheral blood mononuclear leukocytes in immunocompetent individuals. These data indicate significant differences between the prevalence of BKV and JCV infection in healthy blood donors. The prevalence of BK and JC virus infection is higher in the age range 30-39 years compared to other age ranges.
Subject(s)
Humans , Male , Female , Adult , Middle Aged , Young Adult , Tumor Virus Infections/virology , Blood Donors , Leukocytes, Mononuclear/virology , BK Virus/isolation & purification , JC Virus/isolation & purification , Polyomavirus Infections/virology , Tumor Virus Infections/blood , Tumor Virus Infections/epidemiology , DNA, Viral/isolation & purification , Prevalence , Age Distribution , BK Virus/genetics , JC Virus/genetics , Viral Load , Polyomavirus Infections/blood , Polyomavirus Infections/epidemiology , Real-Time Polymerase Chain Reaction , Iran/epidemiologyABSTRACT
BACKGROUND AND PURPOSE: The anti-John-Cunningham virus (JCV)-antibody serostatus and index are used in the risk stratification of progressive multifocal leukoencephalopathy (PML) in multiple sclerosis (MS) patients treated with natalizumab. However, little information on these parameters is available for Asian countries. The purpose of this study was to determine the rate of seropositivity, index, and longitudinal index evolution in Korean patients with MS. METHODS: The antibody seroprevalence was analyzed in 355 samples from 187 patients with clinically isolated syndrome or MS using a second-generation, two-step, enzyme-linked immunosorbent assay. A 4-year longitudinal evaluation was applied to 66 patients. RESULTS: The overall antibody seroprevalence was 80% (n=149). Among antibody-positive patients, the index had a median value of 3.27 (interquartile range, 1.52–4.18), with 77% (n=114) and 56% (n=83) of patients having indices >1.5 and >3.0, respectively. The serostatus of 59 (89%) of the 66 patients did not change during the longitudinal analysis, while 3 (6%) of the 53 patients who were initially seropositive reverted to seronegativity, and 2 (15%) of the 13 patients who were initially seronegative converted to seropositivity. All patients with a baseline index >0.9 maintained seropositivity, and 92% of patients with a baseline index >1.5 maintained this index over 4 years. No patients developed PML (median disease duration, 8 years). CONCLUSIONS: The seroprevalence and index of anti-JCV antibodies in Korean patients with MS may be higher than those in Western countries.
Subject(s)
Humans , Antibodies , Asia , Asian People , Enzyme-Linked Immunosorbent Assay , JC Virus , Leukoencephalopathy, Progressive Multifocal , Multiple Sclerosis , Natalizumab , Seroepidemiologic StudiesABSTRACT
ABSTRACT Treatment options for multiple sclerosis (MS) have changed over the last few years, bringing about a new category of drugs with more efficient profiles. However, these drugs have come with a whole new profile of potential adverse events that neurologists have to learn well and quickly. One of the most feared complications of these MS treatments is progressive multifocal leukoencephalopathy caused by the reactivation of the John Cunningham virus (JCV). Objective: To identify the serologic profile of JCV in patients with MS. Methods: Data on serum antibodies for JCV were obtained using the enzyme-linked immunosorbent assay provided by the STRATIFY-JCV program. Results: A total of 1,501 blood tests were obtained from 1,102 patients with MS. There were 633 patients (57.1%) who were positive for antibodies for JCV and 469 patients who were negative (42.9%). Twenty-three patients became positive after initially having negative JCV antibody status. The rate of seroconversion was 18.5% over 22 months. Conclusion: The JCV serologic profile and seroconversion in Brazilian patients were similar to those described in other countries.
RESUMO As opções terapêuticas para esclerose múltipla (EM) modificaram-se ao longo dos últimos anos, trazendo uma nova categoria de drogas com melhor perfil de eficácia. No entanto, estas drogas vieram com um novo perfil de potenciais eventos adversos que exigem que o neurologista os reconheça bem e rapidamente. Uma das complicações mais temidas destes tratamentos para a EM é a leucoencefalopatia multifocal progressiva (LEMP), causada pela reativação do vírus John Cunningham (JCV). Objetivo: Identificar o perfil sorológico de JCV em pacientes com EM. Métodos: Dados sorológicos de JCV foram obtidos através do ensaio por enzimas imuno-adsorvidas (ELISA) fornecido pelo programa STRATIFY-JCV. Resultados: Um total de 1.501 testes sanguíneos foram obtidos de 1.102 pacientes com EM. O grupo teve 633 pacientes (57,1%) soropositivos para anticorpos anti-JCV e 469 pacientes negativos (42,9%). Vinte e três pacientes se tornaram posivitos após resultados iniciais negativos para anticorpos anti-JCV. A taxa de soroconversão foi 18,5% em 22 meses. Conclusão: O perfil sorológico do JCV e a soroconversão nos pacientes brasileiros foi semelhante àquela descrita em outros países.
Subject(s)
Humans , Male , Female , Adult , Leukoencephalopathy, Progressive Multifocal/immunology , JC Virus/immunology , Polyomavirus Infections/immunology , Antibodies, Viral/blood , Multiple Sclerosis/virology , Brazil/epidemiology , Enzyme-Linked Immunosorbent Assay , Sex Factors , Prevalence , Leukoencephalopathy, Progressive Multifocal/blood , Polyomavirus Infections/epidemiology , Natalizumab/adverse effects , Seroconversion , Multiple Sclerosis/drug therapy , Multiple Sclerosis/bloodABSTRACT
OBJECTIVES: John Cunningham virus (JCV) is a polyoma virus that infects humans, mainly in childhood or adolescence, and presents no symptomatic manifestations. JCV can cause progressive multifocal leukoencephalopathy (PML) in immunosuppressed individuals, including those undergoing treatment for multiple sclerosis (MS) and neuromyelitis optica (NMO). PML is a severe and potentially fatal disease of the brain. The prevalence of JCV antibodies in human serum has been reported to be between 50.0 and 90.0%. The aim of the present study was to review worldwide data on populations of patients with MS and NMO in order to establish the rates of JCV seropositivity in these individuals.METHODS: The present review followed the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines and used the following search terms: “JCV” OR “JC virus” AND “multiple sclerosis” OR “MS” OR “NMO” OR “neuromyelitis optica” AND “prevalence.” These terms were searched for both in smaller and in larger clusters of words. The databases searched included PubMed, MEDLINE, SciELO, LILACS, Google Scholar, and Embase.RESULTS: After the initial selection, 18 papers were included in the review. These articles reported the prevalence of JCV antibodies in the serum of patients with MS or NMO living in 26 countries. The systematic review identified data on 29,319 patients with MS/NMO and found that 57.1% of them (16,730 individuals) were seropositive for the anti-JCV antibody (range, 40.0 to 69.0%).CONCLUSIONS: The median worldwide prevalence of JCV among adults with MS or NMO was found to be 57.1%.
Subject(s)
Adolescent , Adult , Humans , Antibodies , Brain , JC Virus , Leukoencephalopathy, Progressive Multifocal , Multiple Sclerosis , Natalizumab , Neuromyelitis Optica , Polyomavirus , PrevalenceABSTRACT
Progressive multifocal leukoencephalopathy (PML) is a rare and lethal central nervous demyelinating disease caused by JC polyomavirus (JCV), particularly in patients with impaired immune system. The variation of JCV plays an important role in the pathogenesis of PML, including the recombination of non-coding regulatory region (NCCR), which is closely related to binding sites of transcription factors and affect the level of gene transcription. Nucleotide mutations in VP1 region determine the antigenicity and receptor specificity of JCV, play an important role in cell adsorption, immune-mediation and pathogenicity. In addition, immune cells are also involved in the pathogenesis of PML. T lymphocytes can recognize virus antigens, clear JCV, which are directly related to the prognosis of PML. B lymphocytes can serve as latent sites of JCV, and participate in viral transmission, replication, and coordination of the expression of transcription factors. This paper summarizes the roles of JCV variation and immune cells in pathogenesis of PML.
Subject(s)
Humans , B-Lymphocytes , Allergy and Immunology , Virology , Capsid Proteins , Genetics , Allergy and Immunology , JC Virus , Allergy and Immunology , Leukoencephalopathy, Progressive Multifocal , Pathology , Virology , Mutation , T-Lymphocytes , Allergy and Immunology , VirologyABSTRACT
OBJECTIVES: John Cunningham virus (JCV) is a polyoma virus that infects humans, mainly in childhood or adolescence, and presents no symptomatic manifestations. JCV can cause progressive multifocal leukoencephalopathy (PML) in immunosuppressed individuals, including those undergoing treatment for multiple sclerosis (MS) and neuromyelitis optica (NMO). PML is a severe and potentially fatal disease of the brain. The prevalence of JCV antibodies in human serum has been reported to be between 50.0 and 90.0%. The aim of the present study was to review worldwide data on populations of patients with MS and NMO in order to establish the rates of JCV seropositivity in these individuals. METHODS: The present review followed the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines and used the following search terms: “JCV” OR “JC virus” AND “multiple sclerosis” OR “MS” OR “NMO” OR “neuromyelitis optica” AND “prevalence.” These terms were searched for both in smaller and in larger clusters of words. The databases searched included PubMed, MEDLINE, SciELO, LILACS, Google Scholar, and Embase. RESULTS: After the initial selection, 18 papers were included in the review. These articles reported the prevalence of JCV antibodies in the serum of patients with MS or NMO living in 26 countries. The systematic review identified data on 29,319 patients with MS/NMO and found that 57.1% of them (16,730 individuals) were seropositive for the anti-JCV antibody (range, 40.0 to 69.0%). CONCLUSIONS: The median worldwide prevalence of JCV among adults with MS or NMO was found to be 57.1%.
Subject(s)
Adolescent , Adult , Humans , Antibodies , Brain , JC Virus , Leukoencephalopathy, Progressive Multifocal , Multiple Sclerosis , Natalizumab , Neuromyelitis Optica , Polyomavirus , PrevalenceABSTRACT
Summary Few studies directly compare urinary cytology with molecular methods for detecting BK and JC polyomaviruses. Reactivation of BKV infection is the main risk factor for the development of nephropathy in immunocompromised individuals. The limitation of the cytological method can be attributed to the stage where the infected cell does not have specific and sufficient morphological characteristics for a conclusive diagnosis and can be easily interpreted as degenerative alteration. Moreover, morphologically, it is not possible to differentiate the two types of viruses. Polymerase chain reaction (PCR), not only is a sensitive method, but also allows differentiation of viral types without quantification, and therefore is not indicative of nephropathy. According to the American Society of Nephrology, real-time PCR would be the gold standard to indicate nephropathy because it allows quantifying the number of viral copies.
Resumo Poucos estudos comparam diretamente a citologia urinária com métodos moleculares para detecção de poliomavírus BK e JC. A reativação da infecção por BKV é o principal fator de risco para o desenvolvimento de nefropatia em indivíduos imunocomprometidos. A limitação do método citológico pode ser atribuída ao estágio em que a célula infectada não possui características morfológicas específicas e suficientes para um diagnóstico conclusivo, podendo ser facilmente interpretada como alteração degenerativa. Além do mais, morfologicamente, não é possível diferenciar os dois tipos virais. A reação em cadeia pela polimerase (PCR), além de ser um método sensível, permite diferenciar os tipos virais sem quantificá-los, não sendo, portanto, indicativa de nefropatia. Segundo a American Society of Nephrology, a PCR em tempo real seria o padrão-ouro para indicar nefropatia, pois permite quantificar o número de cópias virais.
Subject(s)
Humans , BK Virus/isolation & purification , JC Virus/isolation & purification , Polyomavirus Infections/virology , DNA, Viral/analysis , Polymerase Chain Reaction , Polyomavirus , BK Virus , JC Virus/genetics , Polyomavirus Infections/diagnosisABSTRACT
Abstract The human polyomaviruses JC and BK (JCPyV and BKPyV) are ubiquitous, species-specific viruses that belong to the family Polyomaviridae. These viruses are known to be excreted in human urine, and they are potential indicators of human wastewater contamination. In order to assess the distribution of both JCPyV and BKPyV in urban water samples collected from a sewage treatment plant (STP) and from a canalized water stream of Porto Alegre, Brazil, two nested-PCR assays were optimized and applied to the samples collected. The amplicons obtained were submitted to sequencing, and the sequences were analyzed with sequences of human polyomaviruses previously deposited in GenBank. Twelve out of 30 water samples (40%) were JCPyV positive, whereas six samples (20%) were BKPyV positive. The sequencing results confirmed the presence of JCPyV subtypes 1 and 3, whereas only BKPyV Ia and Ib were found. This study shows for the first time the presence of human polyomaviruses in surface water and in samples collected in a sewage treatment plant in southern Brazil.
Resumo Os poliomavírus humanos JC e BK (JCPyV e BKPyV) são virus ubíquos, espécie-específicos, pertencentes à família Polyomaviridae. Estes vírus são conhecidos por serem excretados pela urina humana, sendo considerados potenciais indicadores de contaminação por águas residuais urbanas. Buscando acessar a distribuição de JCPyV e BKPyV em amostras de águas coletadas de uma estação de tratamento de esgoto e de um arroio canalizado de Porto Alegre, Brasil, duas técnicas de nested-PCR foram otimizadas e aplicadas às amostras coletadas. Os amplificados obtidos foram submetidos ao sequenciamento e suas sequências analisadas com base em sequências de poliomavírus humanos previamente depositadas no GenBank. Doze de 30 amostras de água (40%) foram positivas para JCPyV, enquanto 6 amostras (20%) foram positivas para BKPyV. Os resultados do sequenciamento confirmaram a presença dos subtipos 1 e 3 de JCPyV, enquanto apenas os BKPyV Ia e Ib foram encontrados. Este estudo demonstra pela primeira vez a presença de poliomavírus humanos em águas superficiais e em amostras coletadas em uma estação de tratamento de esgoto na região sul do Brasil.
Subject(s)
Sewage/virology , BK Virus/isolation & purification , BK Virus/genetics , JC Virus/isolation & purification , JC Virus/genetics , Fresh Water/virology , Genetic Variation , Brazil , Polymerase Chain ReactionABSTRACT
Progressive multifocal leukoencephalopathy (PML) is a devastating neurological disease observed nearly exclusively in immunocompromised patients. Recently, the introduction of monoclonal antibodies significantly inhibiting the immune system such as rituximab has led to an increase in PML cases. Although rituximab-based immunochemotherapy remains the standard of treatment for chronic lymphocytic leukemia (CLL), the importance of Bruton’s tyrosine kinase inhibitors such as ibrutinib is steadily increasing. However, long-term experiences regarding possible side effects of these new substances are rare. Here, we report the development of eventually fatal PML possibly associated with ibrutinib therapy for CLL after multiple prior treatment lines, including rituximab. To the best of our knowledge, this is the first study to report such findings. Since the last course of rituximab was applied over 3 years ago, it is conceivable that the strong B cell inhibition by ibrutinib led to PML. With increased awareness of this potential side effect, further clinical studies are certainly warranted to evaluate this possible association.
Subject(s)
Antibodies, Monoclonal , Immune System , Immunocompromised Host , JC Virus , Leukemia, Lymphocytic, Chronic, B-Cell , Leukoencephalopathy, Progressive Multifocal , Protein-Tyrosine Kinases , RituximabABSTRACT
The polyomavirus are a family of opportunistic virus, which belongs to the JC virus whose primary manifestation is the Progressive Multifocal Leukoencephalopathy and neuronopathy of granulosa cells. Recently given the use of PCR for BK virus in transplant patients have also been described CNS pathologies in relation to this, and most frequent encephalitis and leukoencephalopathy. Each entity has a compatible clinical and genetic testing have allowed a diagnosis of high specificity, however the RNM is the great diagnostic pillar in these pathologies, allowing differentiate the different entities, the progression of lesions and response to treatment, especially in cases where it is indicated antiretroviral therapy, as gadolinium enhancement and mass effect may suggest Syndrome Immune and worse prognosis.
Los Poliomavirus son una familia de virus oportunistas, al cual pertenece el virus JC cuya principal manifestación es la Leucoencefalopatía Multifocal Progresiva y la Neuronopatía de Células Granulosas. Recientemente, dada la utilización de PCR para virus BK en LCR en pacientes trasplantados, también se han descrito patologías de SNC en relación a éste, siendo lo más frecuente la Encefalitis y la Leucoencefalopatía. Cada entidad tiene un contexto clínico compatible y las pruebas genéticas han permitido un diagnóstico de alta especificidad, sin embargo, la RNM es el gran pilar diagnóstico en estas patologías, permitiendo diferenciar las distintas entidades, la progresión de las lesiones y la respuesta a tratamiento, especialmente en los casos en que está indicado la terapia antirretroviral, pues la captación de gadolinio y el efecto de masa pueden sugerir un Síndrome de Reconstitución Inmune y peor pronóstico.
Subject(s)
Humans , Adult , Leukoencephalopathy, Progressive Multifocal/diagnostic imaging , Magnetic Resonance Imaging , BK Virus , JC VirusABSTRACT
ABSTRACT Objective To assess safety of the switch between natalizumab and fingolimod without a washout period. Methods Prospective data on 25 JCV positive patients who underwent this medication switch were collected and analyzed. Results After a median period of nine months from the medication switch, there were no safety issues to report. The patients had good disease control and no adverse events were reported. Conclusion Washout may not be necessary in daily practice when switching from natalizumab to fingolimod. Expertise on multiple sclerosis management, however, is essential for drug switching.
RESUMO Objetivo Avaliar a segurança na mudança entre natalizumabe e fingolimode sem período de washout. Métodos Dados prospectivos de 25 pacientes positivos para vírus JC que tiveram sua medicação modificada foram coletados e analisados. Resultados Após uma mediana de nove meses da troca de medicação, não havia aspectos de segurança a relatar. Os pacientes estavam com bom controle da doença e não foram relatados eventos adversos. Conclusão Washout pode não ser necessário na prática diária para a mudança entre natalizumabe e fingolimode. No entanto, expertise no manejo de esclerose múltipla é essencial para esta troca entre medicações.
Subject(s)
Humans , Male , Female , Adult , Drug Substitution , Fingolimod Hydrochloride/administration & dosage , Natalizumab/administration & dosage , Immunosuppressive Agents/administration & dosage , Multiple Sclerosis/drug therapy , Prospective Studies , Leukoencephalopathy, Progressive Multifocal/complications , Leukoencephalopathy, Progressive Multifocal/virology , Treatment Outcome , JC Virus/drug effects , JC Virus/immunology , Viral Load , Fingolimod Hydrochloride/adverse effects , Natalizumab/adverse effects , Immunosuppressive Agents/adverse effects , Multiple Sclerosis/complicationsABSTRACT
Abstract JC virus (JCV) is a member of the Polyomaviridae family and is associated to a severe disease known as progressive multifocal leukoencephalopathy, PML, which is gradually increasing in incidence as an opportunistic infection among AIDS patients. The present study aimed to investigate the occurrence of JCV among HIV-1 carriers including their types and molecular subtypes and the possible association with disease. Urine samples from 66 HIV-1 infected subjects were investigated for the presence of the virus by amplifying VP1 (215 bp) and IG (610 bp) regions using the polymerase chain reaction. JCV was detected in 32% of the samples. The results confirmed the occurrence of type B (subtype Af2); in addition, another polyomavirus, BKV, was also detected in 1.5% of samples of the HIV-1 infected subjects. Apparently, there was no significant difference between mono- (HIV-1 only) and co-infected (HIV-1/JCV) subjects regarding their TCD4+/TCD8+ lymphocyte counts or HIV-1 plasma viral load. Self admitted seizures, hearing and visual loses were not significantly different between the two groups.
Subject(s)
Humans , Male , Female , Child , Adolescent , Adult , Middle Aged , Young Adult , Leukoencephalopathy, Progressive Multifocal/diagnosis , AIDS-Related Opportunistic Infections/virology , JC Virus/genetics , DNA, Viral/urine , Polymerase Chain Reaction , Cross-Sectional Studies , AIDS-Related Opportunistic Infections/diagnosis , AIDS-Related Opportunistic Infections/urine , JC Virus/isolation & purification , CD4 Lymphocyte Count , Viral Load , Coinfection/virologyABSTRACT
Introducción: Polyomavirus BK (BKPyV) y JC (JCPyV) son patógenos persistentes con capacidad de reactivación en inmunocomprometidos, afectando principalmente el sistema urinario y el sistema nervioso central, respectivamente. No existen estudios chilenos en población infectada por VIH. Objetivo: Detectar la presencia de BKPyV y JCPyV en muestras de sangre de pacientes adultos, chilenos, con infección por VIH y correlacionar los resultados con variables clínicas. Materiales y Métodos: Analizamos 96 muestras de extractos leucocitarios de pacientes del área norte de Santiago. El genoma viral se detectó mediante RPC en tiempo real. Para el análisis estadístico se utilizó las pruebas chi-cuadrado de Pearson y Mann-Whitney, considerando significativo un valor de p < 0,05. Resultados: 33% de las muestras resultaron positivas para BKPyV y se encontró una correlación significativa entre la presencia de genoma de BKPyV y la ausencia de carga viral de VIH. Se evidenció la necesidad de considerar más de un blanco de amplificación del genoma de BKPyV. Todas las muestras fueron negativas para JCPyV. Discusión: La prevalencia de BKPyV en pacientes chilenos con infección por VIH es superior a la informada en la mayoría de los reportes internacionales. Se requiere estudios que evalúen la interacción entre ambos virus. Estos pacientes deberían ser sometidos a controles urológicos y nefrológicos periódicos.
Introduction: Polyomavirus BK (BKPyV) and JC (JCPyV) are persistent pathogens able to reactivate in im-munocompromised patients, involving mostly urinary and central nervous system. There are no Chilean studies in HIV positive patients. Objective: To detect BKPyV and JCPyV in blood of Chilean HIV positive adult patients and to correlate these results with clinical-related variables. Materials and Methods: 96 stored blood samples from HIV patients belonging to the north area of Santiago were analyzed. Viral genomes of both viruses were detected by real-time PCR. For statistical analysis, chi-square (Pearson) and Mann-Whitney tests were used and p-values < 0.05 were considered significant. Results: 33% of the samples were positive for BKPyV and a significant correlation was found between the presence of BKPyV genome and the absence of detectable HIV viral load. We demonstrated the need to consider more than one amplification target to detect the BKPyV genome. All the samples were negative for JCPyV genome. Discussion: BKPyV prevalence in Chilean HIV patients is higher than most of international studies. New studies regarding the interaction between both viruses are required. These patients should undergo periodic evaluations by urologist and nephrologist.
Subject(s)
Humans , Male , Female , Adolescent , Adult , Middle Aged , Aged , Young Adult , HIV Infections/virology , BK Virus/isolation & purification , JC Virus/isolation & purification , Leukocytes/virology , Chile , Sex Factors , Age Factors , Genome, Viral , Statistics, Nonparametric , Viral Load , Electrophoresis, Agar Gel , Real-Time Polymerase Chain ReactionABSTRACT
Background: Studies have shown sodium restriction to have a beneficial effect on blood pressure (BP) of hypertensive patients. Objective: To evaluate the impact of light salt substitution for regular salt on BP of hypertensive patients. Methods: Uncontrolled hypertensive patients of both sexes, 20 to 65 years-old, on stable doses of antihypertensive drugs were randomized into Intervention Group (IG - receiving light salt) and Control Group (CG - receiving regular salt). Systolic BP (SBP) and diastolic BP (DBP) were analyzed by using casual BP measurements and Home Blood Pressure Monitoring (HBPM), and sodium and potassium excretion was assessed on 24-hour urine samples. The patients received 3 g of salt for daily consumption for 4 weeks. Results: The study evaluated 35 patients (65.7% women), 19 allocated to the IG and 16 to the CG. The mean age was 55.5 ± 7.4 years. Most participants had completed the Brazilian middle school (up to the 8th grade; n = 28; 80.0%), had a family income of up to US$ 600 (n = 17; 48.6%) and practiced regular physical activity (n = 19; 54.3%). Two patients (5.7%) were smokers and 40.0% consumed alcohol regularly (n = 14). The IG showed a significant reduction in both SBP and DBP on the casual measurements and HBPM (p < 0.05) and in sodium excretion (p = 0.016). The CG showed a significant reduction only in casual SBP (p = 0.032). Conclusions: The light salt substitution for regular salt significantly reduced BP of hypertensive patients. .
Fundamento: Alguns estudos demostraram um efeito benéfico da restrição de sódio na pressão arterial (PA) de hipertensos. Objetivo: Avaliar o impacto da substituição do sal comum por sal light na PA de hipertensos. Métodos: Hipertensos não controlados, de ambos os sexos, com idades entre 20 e 65 anos, e usando doses estáveis de anti-hipertensivos foram randomizados para um Grupo Intervenção (GI - recebendo sal light) e um Grupo Controle (GC - recebendo sal comum). A PA sistólica (PAS) e a PA diastólica (PAD) foram analisadas usando-se medidas casuais da PA e Monitoração Residencial da Pressão Arterial (MRPA), e a excreção de sódio e potássio foi avaliada em amostras de urina de 24 horas. Os pacientes receberam 3 g de sal para consumo diário por 4 semanas. Resultados: Este estudo avaliou 35 pacientes (65,7% mulheres), 19 alocados no GI e 16 no GC. A idade média foi de 55,5 ± 7,4 anos. A maioria dos participantes havia completado o ensino fundamental (até a 8a série; n = 28; 80,0%), tinha renda familiar de até dois salários mínimos (n = 17; 48,6%) e praticava atividade física regularmente (n = 19; 54,3%). Dois pacientes (5,7%) eram fumantes e 40,0% consumiam álcool com regularidade (n = 14). O GI mostrou uma significativa redução tanto da PAS quanto da PAD nas medidas casuais e de MRPA (p < 0,05) e, ainda, diminuição da excreção de sódio (p = 0,016). O GC apresentou redução significativa apenas na medida casual da PAS (p = 0,032). Conclusões: A substituição do sal comum por sal light diminuiu significativamente a PA de hipertensos. .
Subject(s)
Female , Humans , Male , Alleles , Haplotypes , HLA-DQ beta-Chains/genetics , HLA-DRB1 Chains/genetics , JC Virus , Polyomavirus Infections/genetics , /immunology , HLA-DQ beta-Chains/immunology , HLA-DRB1 Chains/immunology , Polyomavirus Infections/immunology , Scandinavian and Nordic CountriesABSTRACT
Novas abordagens clínicas para o diagnóstico e monitoramento de pessoas com doenças sistêmicas têm sido empregadas, através da utilização de fluidos biológicos orais, como a saliva e o fluido gengival crevicular (FGC). Alguns autores têm avaliado o potencial desses fluidos no diagnóstico e acompanhamento de doenças, por apresentarem vantagens tais como coleta não invasiva e segurança no manuseio. Até o presente momento, poucos trabalhos detectaram os poliomavírus humano BK (BKV) e JC (JCV) em saliva e nenhum trabalho procurou sua presença no FGC. Esses poliomavírus infectam assintomaticamente cerca de 80% da população geral, mantendo-se latente no trato urinário. No caso de imunossupressão mediada por células, pode ocorrer o aumento da replicação e indução de reação inflamatória. Uma das doenças causadas pela replicação do BKV é a nefropatia associada ao poliomavírus (NAP), caracterizada pela disfunção e perda do próprio rim ou do rim transplantado, enquanto a Leucoencefalopatia Multifocal Progressiva (LMP), causada pela replicação do JCV, infecta os oligodendrócitos, causando desmielinização. Métodos não invasivos para o screening dos poliomavírus podem facilitar a detecção de novos casos e a monitoração de casos previamente conhecidos. O objetivo deste estudo foi verificar a possibilidade de detecção e quantificação do BKV e JCV em fluidos orais (saliva, lavado bucal e FGC) de indivíduos com insuficiência renal crônica (IRC), transplantados renais (TR), e controles em relação ao sangue e urina, fluidos frequentemente usados para esse teste.
Para tanto, foram incluídos no estudo 38 sujeitos, divididos em 3 grupos, sendo 14 indivíduos no grupo com IRC (GIR), 12 TR no grupo transplantado renal (GTR) e 12 indivíduos saudáveis no grupo controle (GC). No total, coletamos 283 amostras dos participantes, sendo 151 de FGC, 38 amostras de saliva, 38 de lavado bucal, 35 de soro e 21 amostras de urina. No GIR, 100% (14) dos indivíduos apresentaram positividade para BKV em pelo menos uma amostra analisada e 14% (2) foram positivos para JCV. No GTR, 91,7% (11) dos indivíduos foram positivos para BKV e 51,7% (5) foram positivos para JCV. Dentre os sujeitos do GC, 91,7% (11) foram positivos para BKV e 50% (6) para JCV, em pelo menos uma amostra testada. Não houve diferença de frequência de detecção viral entre os 3 grupos de participantes, com relação às amostras coletadas. As amostras de fluidos orais (saliva, lavado e FGC) exibiram alta prevalência de detecção, principalmente do BKV, com muitas amostras com níveis quantificáveis de carga viral. Concluímos que fluidos orais, especialmente saliva e lavado bucal, podem ser usados para o rastreamento do BKV e JCV.
New clinical approaches for diagnosis and monitoring of individuals with systemic diseases have been employed through the use of oral biological fluids such as saliva and gingival crevicular fluid (GCF). Some authors have evaluated the potential of these fluids in the diagnosis and monitoring of diseases, because they have advantages such as noninvasive collection and safe handling. To date, few studies have demonstrated the detection of human polyomavirus BK (BKV) and JC (JCV) in saliva and no study reached for its presence in GCF. These polyomavirus infect asymptomatically around 80% of general population, remaining latent in the urinary tract. In case of immunosuppression mediated by cells, there is increased inflammation and induction of replication. One of the diseases caused by BKV replication is polyomavirus associated to the nephropathy (PVAN), characterized by the dysfunction or loss of the kidney or transplanted kidney, while the progressive multifocal leukoencephalopathy (PML) is caused by replication of JCV, infects oligodendrocytes causing demyelination. Noninvasive screening could facilitate the detection of new cases and monitoring of cases previously known. The objective of this study was to investigate the possibility of BKV and JCV detection and quantification in oral fluids
(saliva, mouthwash and GCF) of individuals with chronic kidney failure (CKF), kidney transplantation (KT), and controls compared with blood and urine, often used for this test. Therefore, we included 38 subjects, divided into 3 groups, being 14 individuals with CKF (KFG), 12 individuals with KT (KTG) and 12 healthy control individuals (CG). In a total, we collected 283 samples, being 151 of GCF, 38 of saliva, 38 of mouthwash, 35 of serum and 21 samples of urine. In the KFG, 100% (14) of the individuals were positive for BKV in at least one of the collected sample and 14% (2) were positive for JCV. In the KTG, 91.7% (11) were positive for BKV and 51.7% for JCV. Among the subjects of the CG, 91.7% (11) were positive for BKV and 50% (6) to JCV, in at least one tested sample. There was no difference in viral detection frequency between the 3 studied groups with respect to the collected samples. Oral fluids samples (saliva, mouthwash and GCF) exhibited high prevalence of detection, especially of BKV, and several samples showed detectable viral load. We conclude that oral fluids, especially saliva and mouthwash, can be used for the screening of BKV and JCV.